641 related articles for article (PubMed ID: 34738881)
1. Multi-Omics analysis identifies a lncRNA-related prognostic signature to predict bladder cancer recurrence.
Xu Z; Chen H; Sun J; Mao W; Chen S; Chen M
Bioengineered; 2021 Dec; 12(2):11108-11125. PubMed ID: 34738881
[TBL] [Abstract][Full Text] [Related]
2. A potential prognostic lncRNA signature for predicting survival in patients with bladder urothelial carcinoma.
Bao Z; Zhang W; Dong D
Oncotarget; 2017 Feb; 8(6):10485-10497. PubMed ID: 28060759
[TBL] [Abstract][Full Text] [Related]
3. Integrative analysis of prognostic long non-coding RNAs with copy number variation in bladder cancer.
Zhong W; Wang D; Yao B; Chen X; Wang Z; Qu H; Ma B; Ye L; Qiu J
J Zhejiang Univ Sci B; 2021 Aug; 22(8):664-681. PubMed ID: 34414701
[TBL] [Abstract][Full Text] [Related]
4. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
[TBL] [Abstract][Full Text] [Related]
5. Prognosis analysis and validation of lipid metabolism-associated lncRNAs and tumor immune microenvironment in bladder cancer.
Tan Z; Fu S; Zuo J; Wang J; Wang H
Aging (Albany NY); 2023 Aug; 15(16):8384-8407. PubMed ID: 37632832
[TBL] [Abstract][Full Text] [Related]
6. Identification of a novel defined inflammation-related long noncoding RNA signature contributes to predicting prognosis and distinction between the cold and hot tumors in bladder cancer.
Xiong X; Chen C; Li X; Yang J; Zhang W; Wang X; Zhang H; Peng M; Li L; Luo P
Front Oncol; 2023; 13():972558. PubMed ID: 37064115
[TBL] [Abstract][Full Text] [Related]
7. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
[TBL] [Abstract][Full Text] [Related]
8. A novel cuproptosis-related lncRNA signature predicts the prognosis and immune landscape in bladder cancer.
Bai Y; Zhang Q; Liu F; Quan J
Front Immunol; 2022; 13():1027449. PubMed ID: 36451815
[TBL] [Abstract][Full Text] [Related]
9. Identifying a Novel Defined Pyroptosis-Associated Long Noncoding RNA Signature Contributes to Predicting Prognosis and Tumor Microenvironment of Bladder Cancer.
Lu H; Wu J; Liang L; Wang X; Cai H
Front Immunol; 2022; 13():803355. PubMed ID: 35154117
[TBL] [Abstract][Full Text] [Related]
10. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.
Gu JX; Zhang X; Miao RC; Xiang XH; Fu YN; Zhang JY; Liu C; Qu K
World J Gastroenterol; 2019 Jan; 25(2):220-232. PubMed ID: 30670911
[TBL] [Abstract][Full Text] [Related]
11. Identification and validation of telomerase related lncRNAs signature to predict prognosis and tumor immunotherapy response in bladder cancer.
Chen X; Qin Z; Zhu X; Wang L; Li C; Wang H
Sci Rep; 2023 Dec; 13(1):21816. PubMed ID: 38071230
[TBL] [Abstract][Full Text] [Related]
12. Identification of immune-related LncRNA for predicting prognosis and immunotherapeutic response in bladder cancer.
Wu Y; Zhang L; He S; Guan B; He A; Yang K; Gong Y; Li X; Zhou L
Aging (Albany NY); 2020 Nov; 12(22):23306-23325. PubMed ID: 33221763
[TBL] [Abstract][Full Text] [Related]
13. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
Wang Z; Tu L; Chen M; Tong S
BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
[TBL] [Abstract][Full Text] [Related]
14. A robust signature of immune-related long non-coding RNA to predict the prognosis of bladder cancer.
Lai C; Wu Z; Li Z; Yu H; Li K; Tang Z; Liu C; Xu K
Cancer Med; 2021 Sep; 10(18):6534-6545. PubMed ID: 34374227
[TBL] [Abstract][Full Text] [Related]
15. Genome-wide Exploration of a Pyroptosis-Related Long Non-Coding RNA Signature Associated With the Prognosis and Immune Response in Patients With Bladder Cancer.
Gao X; Cai J
Front Genet; 2022; 13():865204. PubMed ID: 35571063
[No Abstract] [Full Text] [Related]
16. An eight-long non-coding RNA signature as a candidate prognostic biomarker for bladder cancer.
Lian P; Wang Q; Zhao Y; Chen C; Sun X; Li H; Deng J; Zhang H; Ji Z; Zhang X; Huang Q
Aging (Albany NY); 2019 Sep; 11(17):6930-6940. PubMed ID: 31479417
[TBL] [Abstract][Full Text] [Related]
17. Prediction of bladder cancer outcome by identifying and validating a mutation-derived genomic instability-associated long noncoding RNA (lncRNA) signature.
Wu H; Zhang ZY; Zhang Z; Xiao XY; Gao SL; Lu C; Zuo L; Zhang LF
Bioengineered; 2021 Dec; 12(1):1725-1738. PubMed ID: 33955803
[TBL] [Abstract][Full Text] [Related]
18. A prognostic index based on a fourteen long non-coding RNA signature to predict the recurrence-free survival for muscle-invasive bladder cancer patients.
Zhang X; Zhang M; Zhang X; Zhu X; Wang J
BMC Med Inform Decis Mak; 2020 Jul; 20(Suppl 3):136. PubMed ID: 32646427
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer.
Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
Lipids Health Dis; 2021 Oct; 20(1):146. PubMed ID: 34706720
[TBL] [Abstract][Full Text] [Related]
20. Predicting Prognosis and Distinguishing Cold and Hot Tumors in Bladder Urothelial Carcinoma Based on Necroptosis-Associated lncRNAs.
Liu D; Xu S; Chang T; Ma S; Wang K; Sun G; Chen S; Xu Y; Zhang H
Front Immunol; 2022; 13():916800. PubMed ID: 35860239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
